Benzinga | Jan 14, 2021 07:46AM EST

Citigroup Downgrades Vanda Pharmaceuticals to Neutral, Announces $14 Price Target

Citigroup analyst Joel Beatty downgrades Vanda Pharmaceuticals (NASDAQ:VNDA) from Buy to Neutral and announces $14 price target.